Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.54 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.40 |
| ▸ | GRB2 | P62993 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408661 | 1.00 | CAPN1 (0.54) | CAPN1CTSBOPRM1OPRD1BDKRB2 | |
| SCHEMBL20769305 | 1.00 | CAPN1 (0.54) | CAPN1CTSBOPRM1OPRD1BDKRB2 | |
| SCHEMBL29760883 | 0.96 | CAPN1 (0.55) | CAPN1CTSBOPRM1OPRD1BDKRB2 | |
| SCHEMBL30184771 | 0.93 | OPRM1 (0.47) | CAPN1CTSBOPRM1OPRD1BDKRB2 | |
| SCHEMBL29595585 | 0.93 | OPRM1 (0.47) | CAPN1CTSBOPRM1OPRD1BDKRB2 | |
| SCHEMBL30321101 | 0.91 | CAPN1 (0.46) | CAPN1CTSBOPRM1OPRD1BDKRB2 | |
| SCHEMBL29397120 | 0.89 | CAPN1 (0.49) | CAPN1CTSBOPRM1OPRD1 | |
| SCHEMBL20769303 | 0.89 | CAPN1 (0.41) | CAPN1CTSBOPRM1OPRD1BDKRB2 | |
| SCHEMBL19492654 | 0.89 | CAPN1 (0.51) | CAPN1CTSBOPRM1OPRD1BDKRB2 | |
| SCHEMBL31752434 | 0.89 | CAPN1 (0.48) | CAPN1CTSBOPRM1OPRD1BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289897-A1 | LEPTIN RECEPTOR AGONISTIC ANTIBODY AS MONO OR COMBO THERAPIES TO TREAT OBESITY | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CAPN1 2889/4885CTSB 1261/4885OPRM1 2317/4885 |
| US-20250289897-A1 | LEPTIN RECEPTOR AGONISTIC ANTIBODY AS MONO OR COMBO THERAPIES TO TREAT OBESITY | ADIPOR1, ADIPOR2, GPR119 | CAPN1 1484/4885CTSB 1963/4885OPRM1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.